Biotech cash calls and FDA delays drive a mixed healthcare week

• Nyrada fell 28.77% after announcing a $12 million placement that will fund trials but dilute existing holders.
• Memphasys dropped 16.67% as investors weighed a possible US approval route that still needs FDA feedback.
• Nexsen fell 15.15% after delaying its StrepSure submission and suspending trading pending a contract update.
• Telix plans to buy ITM for US$1.65 billion, gaining control of a radiopharmaceutical supply chain but taking on dilution and regulatory risk.